新冠后综合征治疗随机适应性评估(RAPID):一项多中心、随机、对照适应性平台试验的研究方案,评估新冠后综合征(PCS)患者物理功能的治疗选择,包括首个干预特定附录RAPID_REVIVE(减轻PCS患者炎症活动)
RAPID是一项多中心、随机、对照适应性平台试验,主要评估不同PCS治疗对患者整体物理功能的影响。首个干预特定附录RAPID_REVIVE为双盲、安慰剂对照II期试验,评估vidofludimus calcium(IMU-838)抗病毒治疗PCS,主要结局为SF-36-PF从基线至第56天的患者内变化。
要点
- RAPID为适应性平台试验,含主方案和干预特定附录,首个附录为RAPID_REVIVE。
- RAPID_REVIVE采用双盲、安慰剂对照设计,评估vidofludimus calcium(IMU-838)治疗PCS。
- 主要结局为SF-36-PF从基线至第56天的患者内变化。
核心结论
- RAPID旨在建立适应性平台试验方案,以协调和加速评估PCS不同潜在治疗的疗效与安全性,扩展PCS治疗极为有限的证据基础。
- 目前PCS患者缺乏循证治疗选择,生活质量和心理健康常显著受损。
研究设计与样本
- RAPID为多中心、随机、对照适应性平台试验,采用主方案设计,包含所有通用信息,当前和未来的研究治疗在干预特定附录中规定。
- 首个干预特定附录RAPID_REVIVE为双盲、安慰剂对照II期临床试验,评估vidofludimus calcium(IMU-838)抗病毒治疗PCS。
- 患者按1:1比例随机分配至vidofludimus calcium 45 mg/天(最初7天为22.5 mg)或安慰剂,初始化阶段后采用反应适应性随机化程序。
- 试验包括7天筛选期、56天双盲治疗期和28天随访期。
主要发现
- 主要结局为SF-36物理功能(SF-36-PF)从基线至第56天的患者内变化。
- 次要终点包括心理和身体健康、疲劳强度、精神障碍症状严重程度和认知功能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS). Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. In conclusion, there is an evident medical need to identify treatments for patients with PCS. METHODS: The primary objective of the platform trial RAPID is to assess the impact of different PCS treatments on the overall physical function of patients. Designed as a master protocol, RAPID contains all information that is generic to this adaptive platform trial. Current and future study treatments are specified in intervention-specific appendices (ISA). The first ISA, RAPID_REVIVE is presented in this manuscript. General sections of the master protocol are named as such. RAPID_REVIVE is a double-blind, placebo-controlled, phase II clinical trial evaluating antiviral PCS treatment with vidofludimus calcium (IMU-838). Patients are randomized at a 1:1 ratio to 45 mg/day vidofludimus calcium (22.5 mg for the first 7 days) or placebo during an initialization phase and thereafter using a response-adaptive randomization procedure. The trial includes a screening period of 7 days, a double-blind treatment period of 56 days and a follow-up period of 28 days. The primary outcome is the intra-patient change in physical function measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56. Secondary endpoints include mental and physical health, intensity of fatigue, severity of mental disorder symptoms, and cognitive function. DISCUSSION: PCS is a major problem for global health care and the identification of treatment options is urgently needed. Currently, PCS patients are in a situation without evidence-based treatment options, and quality of life, and often mental health are significantly impaired. The purpose of RAPID is to establish an adaptive platform trial protocol which will concert and quicken clinical trials to evaluate the efficacy and safety of different potential treatments for PCS with the aim to expand the very limited evidence base for the treatment of PCS. TRIAL REGISTRATION: EU Clinical Trials Register (CTIS) ID: 2024-511628-16-00 (RAPID_REVIVE). Registered on 18.03.2024.
引用
- Weipert L, Telgmann RG, Anton G, et al. Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS). Trials. 2025. PMID: 40830806. doi:10.1186/s13063-025-09008-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。